by Stefanie Desmet, Jan Verhaegen, Marc Van Ranst, Willy Peetermans, Katrien Lagrou
The Lancet Infectious Diseases, DOI: https://doi.org/10.1016/S1473-3099(18)30346-3
Pneumococcal vaccination is the cornerstone in the prevention of invasive pneumococcal disease. The use of the first pneumococcal conjugate vaccine in children, the 7-valent pneumococcal conjugate vaccine (PCV7), resulted in an important decline in vaccine serotype invasive pneumococcal disease. However, due to serotype replacement by serotypes not included in PCV7, the introduction of this vaccine was associated with a subsequent increase in non-vaccine serotypes. New conjugate vaccines were developed, including a 10-valent conjugate vaccine, PCV10 (including PCV7 serotypes plus ST1, ST5, ST7F), and a 13-valent vaccine, PCV13 (including PCV10 serotypes plus ST3, ST19A, ST6A). However, it is not clear which of these two vaccines should be used in childhood immunisation programmes because of uncertainties about serotype replacement, herd effects, and serotype-cross protection.